Gynecologic Oncology
RSSArticles
-
Postpartum LARCs help avert repeat pregnancy
-
The search has begun for long-acting contraceptives
FHI 360 has launched its Contraceptive Technology Innovation Initiative to develop innovative, long-acting contraceptives. -
Lower unintended pregnancy rates: Use IUD for emergency contraception
Women seeking emergency contraception (EC) are at high risk of unintended pregnancy. -
STI: Initial positive results reported on herpes vaccine — What’s next?
Some 776,000 U.S. residents incur new genital herpes infections annually. There is no cure. Initial, positive results are reported for a therapeutic vaccine candidate for treating genital herpes. -
Attacks continue on family planning funds
The last several years have brought unprecedented attacks on the publicly supported family planning effort in the United States. -
IUD for EC: Check the Utah experience
Can increased use of the copper T intrauterine device (ParaGard IUD, Teva Womens Health, North Wales, PA) for emergency contraception (EC) make an impact on the rate of unplanned pregnancy at your clinic? -
STI: HPV linked to rise in oropharyngeal cancer
Human papillomavirus (HPV) might be to blame for the rise of young adults with oropharyngeal cancer. -
STI: New report issued on antibiotic resistance
-
Enhance your practice by adding Selected Practice Recommendations
This new evidence-based guidance from the CDC will improve and streamline how we provide contraceptive services to our patients, says Andrew Kaunitz, MD -
New intrauterine device now is in research
An experimental levonorgestrel 20 mcg intrauterine device (LNG20 IUD) is under development by Medicines360, a San Francisco-based nonprofit pharmaceutical company.